IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD

IAM Advisory LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,375 shares of the biopharmaceutical company’s stock, valued at approximately $1,273,000.

Other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Gilead Sciences during the second quarter worth $2,150,268,000. Invesco Ltd. raised its stake in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after buying an additional 1,618,453 shares during the last quarter. Amundi boosted its holdings in Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after acquiring an additional 1,614,355 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after acquiring an additional 400,002 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

GILD opened at $137.21 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The firm has a 50 day moving average of $142.69 and a two-hundred day moving average of $127.77. The firm has a market capitalization of $170.34 billion, a PE ratio of 20.27, a P/E/G ratio of 1.85 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 309,280 shares of company stock worth $44,068,850. Corporate insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of recent analyst reports. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Wolfe Research lifted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Finally, Daiwa Securities Group raised their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.